Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 03 - 07 tags : Phase 3 save search
Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause
Published: 2022-03-07 (Crawled : 14:30) - biospace.com/
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 1.58%
H: 0.0%
C: -0.87%
treatment topline results topline phase 3
Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer
Published: 2022-03-07 (Crawled : 14:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -2.66%
H: 0.0%
C: 0.0%
cs-02 cancer phase 3 breast cancer her2- her2 metastatic breast cancer
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
EVAX | $4.06 -1.93% -1.97% 10K
|
Manufacturing
|
| O: -0.7%
H: 8.77%
C: -2.81%
evx-02 trial phase 1 biotech iot phase 2 phase 3
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
Published: 2022-03-07 (Crawled : 13:30) - biospace.com/
OPTN | $0.92 -4.93% -5.18% 570K
|
Health Services
|
| O: -3.89%
H: 0.0%
C: 0.0%
pos trial report positive results phase 3 topline
Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress
Published: 2022-03-07 (Crawled : 12:30) - biospace.com/
RPTX 4 | $3.3 -1.79% -1.82% 73K
|
Health Technology
|
| O: -5.48%
H: 5.02%
C: 1.56%
rp-3500 500 trial therapeutics phase 1 therapy cancer phase 2 phase 3
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial
Published: 2022-03-07 (Crawled : 12:30) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.5%
H: 1.66%
C: 0.93%
ynote-716 keytruda trial therapy phase 3
KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial
Published: 2022-03-07 (Crawled : 12:00) - ir.kalvista.com
KALV | News | $10.34 -7.76% -8.41% 420K
|
Health Technology
|
| O: -2.65%
H: 0.0%
C: 0.0%
kvd900 als trial phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.